Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A large study examining the cardiovascular drug Diovan in Japanese patients has demonstrated a significant reduction in blood pressure and protection of organs, according to the drug's manufacturer Novartis.
Subscribe to our email newsletter
In the study, Diovan was added to conventional therapy to control blood pressure and protect against cardiovascular events and stroke. The results showed significant benefit with the use of, including a 39% decrease in cardiovascular events and a 40% decrease in stroke compared to conventional non-ARB therapy.
Furthermore, treatment was initiated in a population with an average starting blood pressure of 139/81 mmHg – already below the national guideline level for hypertension without comorbidities. The blood pressure target was set at 130/80 mmHg. The non-ARB group achieved 132/78 mmHg and the Diovan group achieved 131/77 mmHg. The Diovan group also showed a 65% reduction in angina pectoris, 46% in heart failure and 81% in aortic dissection.
The study was terminated earlier than anticipated due to superior outcomes for the Diovan group over the control group.